Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors.
暂无分享,去创建一个
T. Kroll | M. Untch | I. Runnebaum | K. Pachmann | O. Camara | S. Krauspe | M. Gajda | C. Jörke | U. Hammer | C. Rabenstein | S. Oppel